IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by 2025, reflecting ...

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by ...

MitoRx Therapeutics strengthens its leadership with the appointments of Lubor Gaal as chief business officer and Stacey ...

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...